Literature DB >> 17026827

Scleritis complicating zoledronic acid infusion.

David Benderson1, Joyson Karakunnel, Sajeev Kathuria, Ashraf Badros.   

Abstract

We present a case of severe unilateral posterior scleritis associated with zoledronic acid administration that was recognized and treated in a timely manner. Subsequent use of pamidronate was associated with milder inflammation in the same eye that eventually resolved with continued monthly infusions, indicating the possibility of immunologic tolerance. Physicians prescribing these drugs should be aware of this side effect, which, if not recognized and treated appropriately, is potentially devastating. We review the published data as well as the current treatment recommendations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17026827     DOI: 10.3816/CLM.2006.n.053

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma        ISSN: 1557-9190


  10 in total

Review 1.  Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature.

Authors:  Obi C Umunakwe; David Herren; Stephen J Kim; Sahar Kohanim
Journal:  Digit J Ophthalmol       Date:  2017-12-28

Review 2.  Safety of long-term bisphosphonate therapy for the management of osteoporosis.

Authors:  E Michael Lewiecki
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

Review 3.  Zoledronic acid in genitourinary cancer.

Authors:  M A Climent; U Anido; M J Méndez-Vidal; J Puente
Journal:  Clin Transl Oncol       Date:  2013-04-25       Impact factor: 3.405

Review 4.  Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.

Authors:  Ronald C Hamdy
Journal:  Drug Des Devel Ther       Date:  2010-11-18       Impact factor: 4.162

5.  A case report: zoledronic acid-induced anterior uveitis.

Authors:  Saadettin Kilickap; Yasemin Ozdamar; M Kadri Altundag; Omer Dizdar
Journal:  Med Oncol       Date:  2007-09-08       Impact factor: 3.064

Review 6.  Ocular Involvement in Systemic Autoimmune Diseases.

Authors:  Elena Generali; Luca Cantarini; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2015-12       Impact factor: 8.667

7.  Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.

Authors:  Michael Pazianas; Cyrus Cooper; F Hal Ebetino; R Graham G Russell
Journal:  Ther Clin Risk Manag       Date:  2010-07-21       Impact factor: 2.423

8.  A rare case of zolendronate infusion complication leading to glaucoma filtration surgery.

Authors:  A Khan; G Lascaratos; T Rane-Malcolm; R Sanders
Journal:  Clin Ophthalmol       Date:  2011-08-18

Review 9.  Orbital Inflammation Caused by Aminobisphosphonates.

Authors:  J Gonzalez Barlatay; C Pagano Boza; G V Hernandez Gauna; J E Premoli
Journal:  J Ophthalmic Vis Res       Date:  2022-01-21

10.  Drug-induced uveitis.

Authors:  Nikolas Js London; Sunir J Garg; Ramana S Moorthy; Emmett T Cunningham
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-03-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.